Brent K Hollenbeck

List of Publications by Year
in descending order

179	5,792	81900 39	88630 70
papers	citations	h-index	g-index

182	182	182	5908
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet, The, 2006, 368, 1171-1179.	13.7	457
2	The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. European Urology, 2014, 66, 253-262.	1.9	418
3	IDENTIFYING RISK FACTORS FOR POTENTIALLY AVOIDABLE COMPLICATIONS FOLLOWING RADICAL CYSTECTOMY. Journal of Urology, 2005, 174, 1231-1237.	0.4	248
4	Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States. Journal of the National Cancer Institute, 2006, 98, 1134-1141.	6.3	209
5	COMPLICATIONS OF URETEROSCOPY: ANALYSIS OF PREDICTIVE FACTORS. Journal of Urology, 2001, 166, 538-540.	0.4	208
6	A Systematic Review of the Volumeâ€“Outcome Relationship for Radical Prostatectomy. European Urology, 2013, 64, 786-798.	1.9	172
7	Volume, Process of Care, and Operative Mortality for Cystectomy for Bladder Cancer. Urology, 2007, 69, 871-875.	1.0	137
8	Delays in diagnosis and bladder cancer mortality. Cancer, 2010, 116, 5235-5242.	4.1	137
9	Volume-Based Referral for Cancer Surgery: Informing the Debate. Journal of Clinical Oncology, 2007, 25, 91-96.	1.6	129
10	Use of Advanced Treatment Technologies Among Men at Low Risk of Dying From Prostate Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 2587.	7.4	122
11	Determinants of Long-Term Sexual Health Outcome After Radical Prostatectomy Measured by a Validated Instrument. Journal of Urology, 2003, 169, 1453-1457.	0.4	112
12	Ureteroscopic Treatment of Lower Pole Calculi: Comparison of Lithotripsy In Situ and After Displacement. Journal of Urology, 2002, 168, 43-45.	0.4	106
13	Physician-Ownership Of Ambulatory Surgery Centers Linked To Higher Volume Of Surgeries. Health Affairs, 2010, 29, 683-689.	5.2	106
14	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. Journal of Urology, 2016, 196, 405-411.	0.4	89
15	THE REGIONALIZATION OF RADICAL CYSTECTOMY TO SPECIFIC MEDICAL CENTERS. Journal of Urology, 2005, 174, 1385-1389.	0.4	85
16	Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer. Journal of Urology, 2015, 194, 790-798.	0.4	85
17	Costs of Radical Prostatectomy for Prostate Cancer: A Systematic Review. European Urology, 2014, 65, 316-324.	1.9	84
18	Provider Treatment Intensity and Outcomes for Patients With Early-Stage Bladder Cancer. Journal of the National Cancer Institute, 2009, 101, 571-580.	6.3	81

#	Article	IF	Citations
19	Prevalence of 24-Hour Urine Collection in High Risk Stone Formers. Journal of Urology, 2014, 191, 376-380.	0.4	81
20	Laparoscopy for Renal Cell Carcinoma: Diffusion Versus Regionalization?. Journal of Urology, 2006, 176, 1102-1107.	0.4	78
21	The Effects of Adjusting for Case Mix on Mortality and Length of Stay Following Radical Cystectomy. Journal of Urology, 2006, 176, 1363-1368.	0.4	72
22	Growth Of High-Cost Intensity-Modulated Radiotherapy For Prostate Cancer Raises Concerns About Overuse. Health Affairs, 2012, 31, 750-759.	5.2	72
23	Ambulatory Surgery Centers and Outpatient Procedure Use Among Medicare Beneficiaries. Medical Care, 2014, 52, 926-931.	2.4	68
24	Understanding the Costs Associated With Surgical Care Delivery in the Medicare Population. Annals of Surgery, 2020, 271, 23-28.	4.2	61
25	Getting Under the Hood of the Volume-Outcome Relationship for Radical Cystectomy. Journal of Urology, 2007, 177, 2095-2099.	0.4	59
26	Variation in Use of Active Surveillance among Men Undergoing Expectant Treatment for Early Stage Prostate Cancer. Journal of Urology, 2014, 192, 75-81.	0.4	59
27	Safety and Efficacy of Same-Session Bilateral Ureteroscopy. Journal of Endourology, 2003, 17, 881-885.	2.1	58
28	Risk factors for adverse outcomes after transurethral resection of bladder tumors. Cancer, 2006, 106, 1527-1535.	4.1	53
29	Racial differences in treatment and outcomes among patients with early stage bladder cancer. Cancer, 2010, 116, 50-56.	4.1	52
30	Identifying Patients Who are Suitable for Stentless Ureteroscopy Following Treatment of Urolithiasis. Journal of Urology, 2003, 170, 103-106.	0.4	50
31	QUALITY OF CARE: PARTIAL CYSTECTOMY FOR BLADDER CANCERâ€" A CASE OF INAPPROPRIATE USE?. Journal of Urology, 2005, 174, 1050-1054.	0.4	50
32	Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology, 2002, 59, 480-484.	1.0	48
33	Independent surgical validation of the new prostate cancer gradeâ€grouping system. BJU International, 2016, 118, 763-769.	2.5	48
34	Ambulatory Surgery Centers and Their Intended Effects on Outpatient Surgery. Health Services Research, 2015, 50, 1491-1507.	2.0	46
35	Association of the Hospital Readmissions Reduction Program With Surgical Readmissions. JAMA Surgery, 2018, 153, 243.	4.3	45
36	Early impact of Medicare accountable care organizations on cancer surgery outcomes. Cancer, 2016, 122, 2739-2746.	4.1	44

#	Article	IF	Citations
37	Surgical Quality Among Medicare Beneficiaries Undergoing Outpatient Urological Surgery. Journal of Urology, 2012, 188, 1274-1278.	0.4	43
38	Understanding Hospital Readmission Intensity after Radical Cystectomy. Journal of Urology, 2015, 193, 1500-1506.	0.4	43
39	Predictors and Cost of Readmission in Total Knee Arthroplasty. Journal of Arthroplasty, 2018, 33, 2759-2763.	3.1	42
40	Clinical Skills Acquisition for Hand-Assisted Laparoscopic Donor Nephrectomy. Journal of Urology, 2004, 171, 35-39.	0.4	41
41	Regional Variation in Quality of Prostate Cancer Care. Journal of Urology, 2014, 191, 957-963.	0.4	41
42	Understanding the variation in treatment intensity among patients with early stage bladder cancer. Cancer, 2010, 116, 3587-3594.	4.1	38
43	The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 77-81.	1.6	37
44	Ambulatory Surgery Center Market Share and Rates of Outpatient Surgery in the Elderly. Surgical Innovation, 2010, 17, 340-345.	0.9	34
45	Opening of Ambulatory Surgery Centers and Procedure Use in Elderly Patients. Archives of Surgery, 2011, 146, 187.	2.2	34
46	Population Based Trends in the Surgical Treatment of Benign Prostatic Hyperplasia. Journal of Urology, 2012, 188, 1837-1841.	0.4	32
47	Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival. European Urology, 2018, 74, 413-419.	1.9	29
48	Misclassification of Hospital Volume With Surveillance, Epidemiology, and End Resultsâ€"Medicare Data. Surgical Innovation, 2007, 14, 192-198.	0.9	28
49	Expulsive Therapy Versus Early Endoscopic Stone Removal in Patients with Acute Renal Colic: A Comparison of Indirect Costs. Journal of Urology, 2014, 191, 673-677.	0.4	28
50	Prostate Capsule Sparing versus Nerve Sparing Radical Cystectomy for Bladder Cancer: Results of a Randomized, Controlled Trial. Journal of Urology, 2015, 193, 64-70.	0.4	28
51	Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney Stones. Urology, 2016, 93, 45-49.	1.0	27
52	Medication Nonadherence and Effectiveness of Preventive Pharmacological Therapy for Kidney Stones. Journal of Urology, 2016, 195, 648-652.	0.4	27
53	No Differences in Population-based Readmissions After Open and Robotic-assisted Radical Cystectomy: Implications for Post-discharge Care. Urology, 2017, 104, 77-83.	1.0	27
54	Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly. European Urology, 2018, 73, 491-498.	1.9	27

#	Article	IF	Citations
55	Preparing Patients and Partners for Recovery From the Side Effects of Prostate Cancer Surgery: A Group Approach. Urology, 2016, 88, 36-42.	1.0	26
56	A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical Cystectomy. Journal of Urology, 2016, 195, 1362-1367.	0.4	26
57	Robotic surgery in urologic oncology: gathering the evidence. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 421-432.	1.4	25
58	Medicare Payments for Outpatient Urological Surgery by Location of Care. Journal of Urology, 2012, 188, 2323-2327.	0.4	25
59	Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. Health Affairs, 2017, 36, 108-115.	5.2	25
60	Disparities in the use of ambulatory surgical centers: a cross sectional study. BMC Health Services Research, 2009, 9, 121.	2.2	24
61	Comparative Effectiveness of External-Beam Radiation Approaches for Prostate Cancer. European Urology, 2014, 65, 162-168.	1.9	24
62	National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms. Urology, 2018, 120, 96-102.	1.0	24
63	Urologist Ownership of Ambulatory Surgery Centers and Urinary Stone Surgery Use. Health Services Research, 2009, 44, 1370-1384.	2.0	23
64	Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery. Annals of Surgery, 2019, 269, 873-878.	4.2	23
65	Health care reform in 2010: transforming the delivery system to improve quality of care. World Journal of Urology, 2011, 29, 85-90.	2.2	22
66	Ambulatory Surgery Centers and Outpatient Urologic Surgery Among Medicare Beneficiaries. Urology, 2014, 84, 57-61.	1.0	21
67	Use of Nephrectomy at Select Medical Centersâ€"A Case of Follow the Crowd?. Journal of Urology, 2006, 175, 670-674.	0.4	20
68	Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care. Cancer, 2018, 124, 563-570.	4.1	20
69	The Comparative Effectiveness of Treatments for Ureteropelvic Junction Obstruction. Urology, 2018, 111, 72-77.	1.0	20
70	Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer. Urology, 2004, 63, 946-950.	1.0	19
71	Urologist Participation in Medicare Shared Savings Program Accountable Care Organizations (ACOs). Urology, 2016, 90, 76-81.	1.0	19
72	Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 415.e1-415.e6.	1.6	18

#	Article	IF	Citations
73	Adoption of Abiraterone and Enzalutamide by Urologists. Urology, 2019, 131, 176-183.	1.0	18
74	De novo neuroendocrine transdifferentiation in primary prostate cancerâ€“a phenotype associated with advanced clinico-pathologic features and aggressive outcome. Medical Oncology, 2021, 38, 26.	2.5	18
75	Certificate of Need Legislation and the Dissemination of Robotic Surgery for Prostate Cancer. Journal of Urology, 2013, 189, 80-85.	0.4	17
76	Implications of Prostate Cancer Treatment in Men With Inflammatory Bowel Disease. Urology, 2017, 104, 131-136.	1.0	17
77	Underuse of 24-Hour Urine Collection Among Children With Incident Urinary Stones: A Quality-of-care Concern?. Urology, 2014, 84, 457-461.	1.0	16
78	Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. Journal of Urology, 2017, 198, 600-607.	0.4	16
79	The implications of baseline boneâ€health assessment at initiation of androgenâ€deprivation therapy for prostate cancer. BJU International, 2018, 121, 558-564.	2.5	16
80	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. European Urology Oncology, 2019, 2, 119-125.	5.4	16
81	Hospitalâ€physician integration and Medicareâ€™s siteâ€based outpatient payments. Health Services Research, 2021, 56, 7-15.	2.0	16
82	Implications of evolving delivery system reforms for prostate cancer care. American Journal of Managed Care, 2016, 22, 569-75.	1.1	16
83	The utility of lockout valve reservoirs in preventing autoinflation in penile prostheses. International Urology and Nephrology, 2002, 34, 379-383.	1.4	14
84	Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer. Urology, 2014, 84, 373-379.	1.0	14
85	Variation in readmission expenditures after high-risk surgery. Journal of Surgical Research, 2017, 213, 60-68.	1.6	14
86	Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. Urology, 2017, 102, 92-99.	1.0	14
87	Health Care Integration and Quality among Men with Prostate Cancer. Journal of Urology, 2017, 197, 55-60.	0.4	14
88	Technology Diffusion and Diagnostic Testing for Prostate Cancer. Journal of Urology, 2013, 190, 1715-1720.	0.4	13
89	Adherence to Performance Measures and Outcomes among Men Treated for Prostate Cancer. Journal of Urology, 2014, 192, 743-748.	0.4	13
90	A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy. Bladder Cancer, 2016, 2, 251-261.	0.4	13

#	Article	IF	Citations
91	The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval. European Urology Focus, 2018, 4, 711-717.	3.1	13
92	Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2212347.	5.9	13
93	The Impact of Technology Diffusion on Treatment for Prostate Cancer. Medical Care, 2013, 51, 1076-1084.	2.4	12
94	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. Asian Journal of Urology, 2015, 2, 53-58.	1.2	12
95	Patient and Provider Variables Associated with Systemic Treatment of Advanced Prostate Cancer. Urology Practice, 2019, 6, 234-242.	0.5	12
96	Real-World Impact of Minimally Invasive Versus Open Radical Cystectomy on Perioperative Outcomes and Spending. Urology, 2019, 125, 86-91.	1.0	12
97	TESTICULAR HISTOPLASMOSIS. Journal of Urology, 2000, 164, 1652-1652.	0.4	11
98	Cost Analysis of Treatments for Ureteropelvic Junction Obstruction. Journal of Endourology, 2017, 31, 204-209.	2.1	11
99	Practice-Level Adoption of Conservative Management for Prostate Cancer. Journal of Oncology Practice, 2019, 15, e863-e869.	2.5	11
100	Role of Postâ€“Acute Care on Hospital Readmission After High-Risk Surgery. Journal of Surgical Research, 2019, 234, 116-122.	1.6	11
101	Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. Journal of the National Cancer Institute, 2022, 114, 1127-1134.	6.3	11
102	Certificate of Need Regulations and the Diffusion of Intensity-modulated Radiotherapy. Urology, 2012, 80, 1015-1020.	1.0	10
103	Understanding the Diffusion of Ambulatory Surgery Centers. Surgical Innovation, 2015, 22, 257-265.	0.9	10
104	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Medical Oncology, 2015, 32, 249.	2.5	10
105	Anatomical patterns of recurrence following biochemical relapse after postâ€prostatectomy salvage radiation therapy: a multiâ€institutional study. BJU International, 2017, 120, 351-357.	2.5	10
106	Adherence and outâ€ofâ€pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer, 2020, 126, 5050-5059.	4.1	10
107	Radical Cystectomy and Surgical Quality of Care. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 37-42.	4.9	9
108	Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention. Urology, 2015, 86, 30-34.	1.0	9

#	Article	IF	Citations
109	Accountable Care Organizations and Prostate Cancer Care. Urology Practice, 2017, 4, 454-461.	0.5	9
110	De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT). Implementation Science, 2018, 13, 144.	6.9	9
111	Inaugural Readmission Penalties for Total Hip and Total Knee Arthroplasty Procedures Under the Hospital Readmissions Reduction Program. JAMA Network Open, 2019, 2, e1916008.	5.9	9
112	Recurrence, metastasis, and survival after radical prostatectomy in the era of advanced treatments.. Journal of Clinical Oncology, 2022, 40, 5090-5090.	1.6	9
113	Response: Re: Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect. Journal of the National Cancer Institute, 2007, 99, 570-571.	6.3	8
114	Measuring Convalescence After Laparoscopic Surgery. Urology, 2007, 69, 1025-1029.	1.0	8
115	Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations. Cancer, 2018, 124, 3364-3371.	4.1	8
116	Effects of Advanced Practice Providers on Single-specialty Surgical Practice. Annals of Surgery, 2023, 277, e40-e45.	4.2	8
117	Concurrent assessment of obstructive/irritative urinary symptoms and incontinence after radical prostatectomy. Urology, 2002, 59, 389-393.	1.0	7
118	Importance of Perioperative Processes of Care for Length of Hospital Stay after Laparoscopic Surgery. Journal of Endourology, 2006, 20, 776-781.	2.1	7
119	Use of Ureteroscopy Before and After Expansion of Lithotripter Ownership in Michigan. Urology, 2011, 78, 1287-1291.	1.0	7
120	Identifying Better Practices for Early-stage Bladder Cancer. Medical Care, 2011, 49, 1112-1117.	2.4	7
121	Technology Diffusion and Prostate Cancer Quality of Care. Urology, 2014, 84, 1066-1072.	1.0	7
122	Receipt of Best Care According to Current Quality of Care Measures and Outcomes in Men with Prostate Cancer. Journal of Urology, 2015, 193, 500-506.	0.4	7
123	Variation in the Use of Open Pyeloplasty, Minimally Invasive Pyeloplasty, and Endopyelotomy for the Treatment of Ureteropelvic Junction Obstruction in Adults. Journal of Endourology, 2017, 31, 210-215.	2.1	7
124	Urologist Practice Structure and Spending for Prostate Cancer Care. Urology, 2019, 130, 65-71.	1.0	7
125	Episode Payments for Transcatheter and Surgical Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005781.	2.2	7
126	Early cystectomy for clinical stage T1 bladder cancer. Nature Reviews Urology, 2004, 1, 4-5.	1.4	6

#	Article	IF	Citations
127	Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancerâ€“specific Mortality: Competition Between Age and Time to Biochemical Failure. European Urology Oncology, 2018, 1, 276-282.	5.4	6
128	Determinants of quality prostate cancer survivorship care across the primary and specialty care interface: Lessons from the Veterans Health Administration. Cancer Medicine, 2019, 8, 2686-2702.	2.8	6
129	Factors influencing treatment of veterans with advanced prostate cancer. Cancer, 2021, 127, 2311-2318.	4.1	6
130	Phase II clinical trial of intravesical bacillus Calmette-Guerin (BCG) followed by sunitinib for the treatment of high-risk nonmuscle-invasive bladder cancer (NMIBC).. Journal of Clinical Oncology, 2015, 33, 293-293.	1.6	6
131	Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer. Urology, 2018, 116, 68-75.	1.0	5
132	Emergency Department Switching and Duplicate Computed Tomography Scans in Patients With Kidney Stones. Urology, 2018, 114, 41-44.	1.0	5
133	Followup Care after Emergency Department Visits for Kidney Stones: A Missed Opportunity. Urology Practice, 2019, 6, 24-28.	0.5	5
134	Mechanisms of decisionâ€making in preoperative assessment for older adult prostate cancer patientsâ€”A qualitative study. Journal of Surgical Oncology, 2020, 121, 561-569.	1.7	5
135	Comparison of readmission and early revision rates as a quality metric in total knee arthroplasty using the Nationwide Readmission Database. Annals of Translational Medicine, 2020, 8, 687-687.	1.7	5
136	Effects of Laparoscopy on Surgical Discharge Practice Patterns. Urology, 2008, 71, 1029-1034.	1.0	4
137	Using Analytic Morphomics to Understand Short-Term Convalescence after Radical Cystectomy. Bladder Cancer, 2016, 2, 235-240.	0.4	4
138	Characterising â€˜bounceâ€backâ€™ readmissions after radical cystectomy. BJU International, 2019, 124, 955-961.	2.5	4
139	Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees. Urology, 2021, 155, 77-82.	1.0	4
140	Learning from the â€œtail endâ€•of de-implementation: the case of chemical castration for localized prostate cancer. Implementation Science Communications, 2021, 2, 124.	2.2	4
141	Statin Use and Risk of Sepsis After Percutaneous Nephrolithotomy. Journal of Endourology, 2015, 29, 1126-1130.	2.1	3
142	Effects of the Medicare Modernization Act on Spending for Outpatient Surgery. Health Services Research, 2018, 53, 2858-2869.	2.0	3
143	Telemedicine utilization by providers in accountable care organizations. MHealth, 2019, 5, 10-10.	1.6	3
144	Impact of Medicare Office Visit Payment Reform on Urologic Practices. Urology, 2019, 126, 83-88.	1.0	3

#	Article	IF	Citations
145	Characterising potential bone scan overuse amongst men treated with radical prostatectomy. BJU International, 2019, 124, 55-61.	2.5	3
146	Intensity of endâ€ofâ€life care for dualâ€eligible beneficiaries with cancer and the impact of delivery system affiliation. Cancer, 2021, 127, 4628-4635.	4.1	3
147	Urologist Practice Structure and Quality of Prostate Cancer Care. Urology Practice, 2020, 7, 419-424.	0.5	3
148	Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 278-283.	3.8	3
149	Prostate cancer clinical trial completion: The role of geography. Contemporary Clinical Trials, 2021, 111, 106600.	1.8	3
150	Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.. Journal of Clinical Oncology, 2017, 35, 35-35.	1.6	3
151	Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, .	2.9	3
152	Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for deâ€implementation. Cancer, 2018, 124, 3971-3974.	4.1	2
153	Association between PSA values and surveillance quality after prostate cancer surgery. Cancer Medicine, 2019, 8, 7903-7912.	2.8	2
154	Spillover Effects of the Hospital Readmissions Reduction Program on Radical Cystectomy Readmissions. Urology Practice, 2019, 6, 350-356.	0.5	2
155	Resurrecting immortalâ€time bias in the study of readmissions. Health Services Research, 2020, 55, 273-276.	2.0	2
156	Dynamic readmission prediction using routine postoperative laboratory results after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 255-261.	1.6	2
157	Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. Urology, 2021, 147, 127-134.	1.0	2
158	Understanding Variation in the Quality of the Surgical Treatment of Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 278-283.	3.8	2
159	Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology, 2022, 161, 50-58.	1.0	2
160	Feasibility and safety of robot-assisted salvage prostatectomy for recurrent prostate cancer following radiation therapy. Journal of Robotic Surgery, 2008, 2, 81-83.	1.8	1
161	Availability of In-Office Laboratory Services and Use of Prostate Specific Antigen Testing. Urology Practice, 2014, 1, 111-116.	0.5	1
162	Reframing Financial Incentives Around Reducing Readmission After Radical Cystectomy. Urology, 2020, 142, 99-105.	1.0	1

#	Article	IF	Citations
163	Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. Urology, 2021, 148, 134-140.	1.0	1
164	Medicare Accountable Care Organizations and the Adoption of New Surgical Technology. Journal of the American College of Surgeons, 2021, 232, 138-145e2.	0.5	1
165	Aortic valve replacement among patients with Alzheimer's disease and related dementias. Journal of the American Geriatrics Society, 2021, 69, 3468-3475.	2.6	1
166	Understanding treatment disconnect and mortality trends in renal cell carcinoma using tumor registry data.. Journal of Clinical Oncology, 2014, 32, 403-403.	1.6	1
167	Medicare Accountable Care Organizations Reduce Spending on Surgery. American Journal of Accountable Care, 2020, 8, 12-19.	0.1	1
168	The changing landscape of treatment and survival for men with castration-resistant prostate cancer in the era of novel treatments.. Journal of Clinical Oncology, 2022, 40, 67-67.	1.6	1
169	Editorial Comment. Urology, 2012, 79, 1178-1179.	1.0	0
170	Understanding Active Surveillance for Prostate Cancer. JCO Oncology Practice, 2021, 17, OP.20.00929.	2.9	0
171	Commercial Prices for Prostatectomy and Treatment among Younger, Privately Insured Men with Prostate Cancer. Urology Practice, 0, , .	0.5	0
172	Results from the seminal vesicle sparing prostatectomy trial.. Journal of Clinical Oncology, 2014, 32, 55-55.	1.6	0
173	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.. Journal of Clinical Oncology, 2014, 32, 15-15.	1.6	0
174	Prognostic significance of perineural invasion in localized prostate cancer.. Journal of Clinical Oncology, 2015, 33, 30-30.	1.6	0
175	Financial hardship among Medicare beneficiaries prescribed oral targeted therapies for advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, 68-68.	1.6	0
176	AUTHOR REPLY. Urology, 2022, 161, 58.	1.0	0
177	Better Understanding the Timing of Androgen Deprivation (TOAD) Trial Outcomes: Impacts of Prior ADT. JNCI Cancer Spectrum, 0, , .	2.9	0
178	Robotic Surgery for Bladder Cancer. JAMA - Journal of the American Medical Association, 2022, , .	7.4	0
179	Unpacking low-value castration practices using behavior specification to guide de-implementation in prostate cancer care.. Journal of Clinical Oncology, 2022, 40, e17055-e17055.	1.6	0